Clinical Psychopharmacology

S. Nassir Ghaemi, MD, MPH, is a Professor of Psychiatry and Pharmacology at Tufts University School of Medicine, and a Lecturer on Psychiatry at Harvard Medical School in Boston, Massachusetts. He is also Director of Translational Medicine-Neuroscience at Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. Dr. Ghaemi has been active in clinical psychopharmacology practice and research for over two decades, with specialization in depression and bipolar illness. He holds degrees in philosophy and public health, and is a highly published scientific investigator.

• Section I: Basic PsychopharmacologyChapter 1: A New Psychopharmacology NomenclatureChapter 2: Fundamentals of NeurobiologyChapter 3: Fundamental Psychotropic Drug Structures and MechanismsSection II: Clinical Research Concepts for PsychopharmacologyChapter 4: The Limitations of Clinical ExperienceChapter 5: Evidence-based Medicine: Pro and ConChapter 6: Maintenance Treatment Designs: "Enriched," But Not BetterChapter 7: Negative Studies: The Failure to Know What Isn't KnownChapter 8: Side Effects and Generalizability: Beyond p-valuesSection III: Clinical Psychopharmacology of Drug ClassesChapter 9: Monoamine Agonists ("Antidepressants"), Including Dopamine Agonists ("Stimulants")Chapter 10: Dopamine Blockers ("Antipsychotics")Chapter 11: Second Messenger Modifiers ("Mood Stabilizers")Chapter 12: Gabaergic Agonists ("Anxiolytics")Chapter 13: Other Agents (Glutamate Antagonists, Antihistamines, Melatonin Agonists, and Others)Chapter 14: Drug Class Summaries and Dosing GuidelinesChapter 15: Index of Selected Commonly Used Drugs with Brief SummariesSection IV: Clinical Psychopharmacology of Diseases and SyndromesChapter 16: Hippocratic Psychopharmacology: A Non-DSM Approach to Practice Chapter 17: Beyond Symptoms: Diagnostic ValidatorsChapter 18: The Concept of a Diagnostic HierarchyChapter 19: Treatment of Affective IllnessesChapter 20: Anxiety ConditionsChapter 21: Treatment of PersonalityChapter 22: Schizophrenia and Schizoaffective ConditionsChapter 23: AddictionsChapter 24: PTSDSection V: Special TopicsChapter 25: Carcinogenicity of Psychotropic DrugsChapter 26: Seasonal Affective IllnessChapter 27: SuicideChapter 28: ChildrenChapter 29: Older PersonsChapter 30: WomenChapter 31: Ethnic and Racial GroupsChapter 32: Psychopharmacology in Medical IllnessesChapter 33: PolypharmacyChapter 34: Cultural Aspects of PsychopharmacologyChapter 35: Treatment versus EnhancementChapter 36: The Pharmaceutical IndustryChapter 37: Drug Discovery: Future TreatmentsSection VI: The Art of PsychopharmacologyChapter 38: The Diagnostic InterviewChapter 39: The "Med Check"Chapter 40: The Placebo EffectChapter 41: Legal Aspects of Psychopharmacology PracticeChapter 42: Psychology of PsychopharmacologyChapter 43: Innovation in Clinical PracticeChapter 44: Clinical CasesChapter 45: Curbside Consults: Questions and AnswersChapter 46: Key Research Studies in Clinical PsychopharmacologyChapter 47: Historical Insights in PsychopharmacologyChapter 48: Reflections on the Art of PsychopharmacologyChapter 49: Ten Fallacies and Ten Truths of Psychopharmacology - ExplainedAppendicesAppendix I: Mixed StatesAppendix II: Bipolar or Borderline?Appendix III: ADD in Children and AdultsAppendix IV: Schizoaffective Illness

This book will be useful to readers not only because it provides information and rationales on how to treat psychiatric disease, but also because it attempts to cover these topics in a unique way that other books have not.